What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.”In the company’s words, NCT07093268 on ClinicalTrials.gov
- Main trialPhase 1
- “The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.”In the company’s words, NCT07093268 on ClinicalTrials.gov
Other drugs for Amyotrophic Lateral Sclerosis
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 15 Jun 2026 | Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026